

**Manuscript version: Author's Accepted Manuscript**

The version presented in WRAP is the author's accepted manuscript and may differ from the published version or Version of Record.

**Persistent WRAP URL:**

<http://wrap.warwick.ac.uk/143622>

**How to cite:**

Please refer to published version for the most recent bibliographic citation information. If a published version is known of, the repository item page linked to above, will contain details on accessing it.

**Copyright and reuse:**

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions.

Licensed under the Creative Commons Attribution-NonCommercial- 4.0 International

<https://creativecommons.org/licenses/by-nc/4.0/>



**Publisher's statement:**

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: [wrap@warwick.ac.uk](mailto:wrap@warwick.ac.uk).

1 Psychological interventions for depression in children and young people with an intellectual  
2 disability and/or autism: A systematic review

3 Lauren A. Cameron<sup>1</sup>, Katelyn Phillips<sup>2,1</sup>, Glenn A. Melvin<sup>3,4</sup>, Richard P. Hastings<sup>4,1</sup>, Kylie  
4 M. Gray<sup>4,1</sup>

5

6 <sup>1</sup>Centre for Developmental Psychiatry and Psychology, Department of Psychiatry, School of  
7 Clinical Sciences at Monash Health, Monash University, Clayton, Australia

8 <sup>2</sup>Discipline of Paediatrics, School of Women's and Children's Health, UNSW Medicine, The  
9 University of New South Wales (UNSW Sydney), Sydney, Australia

10 <sup>3</sup>School of Psychology, Deakin University, Burwood, Australia

11 <sup>4</sup>Centre for Education, Appraisal and Research (CEDAR), University of Warwick, Coventry,  
12 U.K.

13

14 Corresponding author: Kylie M. Gray

15 [K.Gray.1@warwick.ac.uk](mailto:K.Gray.1@warwick.ac.uk)

## Abstract

16

### 17 **Background**

18 Children and young people with intellectual disability and/or Autism Spectrum Disorder  
19 (autism) experience higher rates of mental health problems, including depression, than their  
20 typically developing peers. While international guidelines suggest psychological therapies as  
21 first line intervention for children and young people, there is limited research evidence for  
22 psychological therapy for depression in children and young people with intellectual disability  
23 and/or autism.

### 24 **Aims**

25 To evaluate the current evidence base for psychological interventions for depression in  
26 children and young people with an intellectual disability and/or autism, and examine the  
27 experiences of children and young people with intellectual disability and/or autism, their  
28 families, and therapists, in receiving and delivering psychological treatment for depression.

### 29 **Method**

30 Databases were searched up to 30 April 2020 using pre-defined search terms and criteria.  
31 Articles were independently screened and assessed for risk of bias. Data were synthesised and  
32 reported in a narrative review format.

### 33 **Results**

34 A total of 10 studies met inclusion criteria. Four identified studies were clinical case reports  
35 and six were quasi-experimental or experimental studies. All studies were assessed as being  
36 of moderate or high risk of bias. Participants with intellectual disability were included in four  
37 studies. There was limited data on the experiences of young people, their families, or  
38 therapists in receiving or delivering psychological treatment for depression.

39 **Conclusion**

40 Well-designed randomised controlled trials are critical to develop an evidence base for  
41 psychological treatment for young people with intellectual disability and/or autism with  
42 depression. Future research should evaluate young people, family, and therapist experience of  
43 treatment.

## Introduction

44  
45 Mental health disorders have been found to be three to five times more prevalent in children  
46 and adolescents with intellectual disability compared to their typically developing peers<sup>1,2</sup>.  
47 Consistent with this general mental health inequity, adolescents with intellectual disability,  
48 Autism Spectrum Disorder (hereafter referred to as autism), or both conditions are at higher  
49 risk for depression than their same-age peers<sup>1,3-6</sup>. Specifically, children and young people  
50 with intellectual disability are 1.7 times more likely to experience depression compared to  
51 other children<sup>5</sup>. Although young people with autism have demonstrated higher rates of  
52 depression than typically developing children and adolescents, reported rates vary  
53 considerably<sup>6</sup>.

54 Treatment for mental health problems in people with intellectual disability has historically  
55 relied on pharmacological approaches<sup>7,8</sup>. However, international guidelines and  
56 recommendations suggest that first line treatments for depression in children and young  
57 people should include psychological therapies<sup>9,10</sup>. There is some support for the use of  
58 cognitive behavioural therapy for depression in adults with mild-moderate intellectual  
59 disability<sup>7</sup> but a lack of research focus on children and adolescents. Research evidence for  
60 the psychological treatment of depression in children and adolescents with autism is available  
61 but limited, with the evidence to-date focused on the treatment of anxiety or disruptive  
62 behaviours<sup>11,12</sup>. The current study, therefore, had the following review questions: (1) What is  
63 the current evidence base for psychological interventions for depression in children and  
64 young people with an intellectual disability and/or autism?, (2) What are the experiences of  
65 children and young people with intellectual disability and/or autism and their family members  
66 of psychological intervention for depression?, and (3) What are the experiences of therapists  
67 delivering psychological intervention for depression to children and young people with  
68 intellectual disability and/or autism?

69

## Method

70 The review protocol was prospectively registered with the International Prospective Register  
71 of Systematic Reviews (PROSPERO, registration number CRD42019145495) and can be  
72 accessed here:

73 [https://www.crd.york.ac.uk/prospERO/display\\_record.php?ID=CRD42019145495](https://www.crd.york.ac.uk/prospERO/display_record.php?ID=CRD42019145495). The review  
74 was conducted and is reported in accordance with the Preferred Reporting Items for  
75 Systematic Reviews and Meta-Analyses (PRISMA) guidelines <sup>13</sup>.

### 76 Search strategy

77 PsycINFO, MEDLINE, Embase via Elsevier, CINAHLPlus, Social Sciences Index and  
78 Sciences Index via Web of Science, and Scopus databases were searched by two authors  
79 (L.A.C and K.P.) on 1<sup>st</sup> May 2020 for articles published from inception to 30<sup>th</sup> April 2020.  
80 Searches were conducted using keywords identified for each domain (see Table 1 for an  
81 example search string) and limited to articles written in English. Hand searching of reference  
82 lists and citation searching of included studies were also conducted to identify potential  
83 additional articles.

84 [INSERT TABLE 1 ABOUT HERE]

### 85 Inclusion/exclusion criteria

86 Studies were included if they met the following criteria:

- 87 a) Study design: pre-post single group designs, case series, clinical case reports, single  
88 case experimental designs, and qualitative studies. Studies with a comparison group,  
89 control group, or no control group were all included. Observational and case-control  
90 studies involving no treatment were excluded.

- 91 b) Participants: children, adolescents, or young people up to age 21 years with an  
92 intellectual disability (including borderline intellectual disability) and/or autism.  
93 Studies were included if the entire sample included the relevant population, or if  
94 outcomes were reported separately for the relevant population. Studies that involved  
95 young people up to the age of 25 years were included if 75% of the sample was under  
96 21 years.
- 97 c) Participant diagnosis: either (i) major depressive disorder as diagnosed by  
98 standardised criteria (e.g. the Diagnostic and Statistical Manual for Mental Disorders,  
99 International Classification of Diseases, Diagnostic Manual-Intellectual Disability),  
100 (ii) dysthymia or minor depression as diagnosed by standardised criteria, or (iii)  
101 depressive status, as defined by meeting cut-offs on a standardised depression  
102 screening questionnaire (e.g., Children's Depression Inventory<sup>14</sup>, Beck Depression  
103 Inventory<sup>15</sup>, Glasgow Depression Scale<sup>16</sup>).
- 104 d) Treatment or intervention: any psychological or psychosocial intervention (e.g. life  
105 skills training, lifestyle intervention) with the aim of treating depression or depressive  
106 symptoms. Pharmacological or medical treatments, transcranial magnetic stimulation,  
107 complementary, and alternative therapies and treatments were excluded.

## 108 **Screening**

109 First stage title and abstract screening was undertaken by two authors (L.A.C. and K.P.) to  
110 identify any articles that were clearly not relevant to the review, with a randomly selected  
111 20% screened by both authors to determine interrater reliability. Agreement was 99.1%  
112 (kappa 0.940). Full text review was independently undertaken by the same two authors with  
113 any conflicts of inclusion/exclusion resolved through discussion, and consultation with  
114 additional authors (K.M.G. and G.A.M.) where necessary (n = 1).

115

116

117 **Data extraction**

118 Data were extracted from each article and coded for: (a) study information (type of study,  
119 country of publication, year of publication), (b) participant information (age, gender,  
120 intellectual disability/autism diagnosis), (c) assessment of depression, (d) treatment  
121 information (type of treatment/intervention, length of treatment, length of follow-up), and (e)  
122 study outcomes.

123 **Risk of bias**

124 Risk of bias assessments were conducted by a panel of four authors (L.A.C., K.P., G.A.M.,  
125 and K.M.G.). Assessments of controlled and uncontrolled trials were conducted using pre-  
126 developed proformas based on the Cochrane risk of bias tool and the Newcastle Ottawa  
127 Scale<sup>17, 18</sup>. These proformas have been used previously in large international systematic  
128 reviews e.g. Blackmore *et al.*<sup>19</sup>. Single case studies and case series were appraised using  
129 criteria described by Horner *et al.*<sup>20</sup>. Each study was assessed overall as being of low,  
130 moderate, or high risk of bias.

131

**Results**

132 A total of 13,936 records were retrieved in the search. After removal of duplicates, 9,343  
133 records remained for abstract and title screening. A further 9,231 records were excluded,  
134 leaving 114 for full text review. No additional articles were identified through reference lists  
135 of included studies or forward citation searching. A total of 10 studies met inclusion criteria  
136 (Figure 1).

137 Summary data for all included studies, including sample description, assessment of  
138 depression, description of treatment and treatment duration, outcome measures, and study  
139 results related to the impact of treatment on depression or depressive symptoms, can be  
140 viewed in Tables 2 and 3.

141 **Research Question 1: What is the evidence base for psychological interventions for**  
142 **depression for children and young people with intellectual disability and/or autism?**

143 Of the 10 included studies, four were clinical case reports<sup>21-24</sup>, and the remaining six were  
144 experimental or quasi-experimental designs, including: one multiple baseline design study<sup>25</sup>,  
145 two uncontrolled group design trials<sup>26, 27</sup>, and three controlled group design trials<sup>28-30</sup>.

146 **Clinical case reports**

147 Across the four clinical case reports, n = 5 participants were described (n = 3 male, ages  
148 ranging from 12 – 18 years). One clinical case report used a combination of psychotherapy  
149 and behavioural training to target depressive symptoms in a 17 year old female with a mild  
150 intellectual disability<sup>21</sup>. Three clinical case reports used adapted versions of cognitive  
151 behavioural therapy (CBT) with a 12 year old male<sup>22</sup>, a 17 year old female<sup>23</sup>, and two males  
152 aged 17 and 18 years old<sup>24</sup>, all with Asperger Syndrome.

153 Three clinical case reports utilising CBT adapted their programme for young people with  
154 autism. Greig and MacKay<sup>22</sup> highlight that their CBT programme, *The Homunculi*, involves  
155 the creation of characters to help the individual to visualise various processes and behaviours.  
156 Loades<sup>23</sup> reported that the CBT programme was adapted for their participant with Asperger  
157 Syndrome, but did not describe what these adaptations involved. Selvapandiyan<sup>24</sup>  
158 implemented *pragmatic CBT*<sup>31</sup>, described by the author as being designed to target the social  
159 communication difficulties evident in Asperger Syndrome. The duration of treatment varied  
160 across the clinical case reports, ranging from 15 individual sessions to eight months.

161 Behavioural training was more intensive, with sessions being undertaken almost daily, while  
162 CBT was undertaken weekly. Behavioural training in these instances involved behavioural  
163 modification of identified behaviours, including compliance, lack of interest, oppositional  
164 behaviours, and self-harm<sup>21</sup>.

165 Three clinical case reports relied on questionnaires to assess change in depressive symptoms  
166 over the course of treatment<sup>22-24</sup>. One clinical case report used the depression scale of the  
167 Briere Trauma Scales (self-report)<sup>32</sup> pre- and post-treatment<sup>22</sup>. Another clinical case report  
168 used the Revised Children's Anxiety and Depression Scales (self-report)<sup>33</sup> at pre-treatment  
169 and throughout the course of treatment at sessions 6, 12 and 20 weeks<sup>23</sup>. The remaining  
170 clinical case report used the Hamilton Depression Rating Scale (HDRS)<sup>34</sup>, rated by the  
171 clinician at the end of each treatment session. The study reported that progress was monitored  
172 over two months post treatment, however, the HDRS scores at follow-up were not reported<sup>24</sup>.

173 All clinical case reports reported an improvement in depressive symptoms following the  
174 intervention, whether that was a decrease in problem behaviours<sup>21</sup>, or a reduction in  
175 depressive scores on screening measures<sup>22-24</sup>. Maintenance of improvements were reported  
176 for the one clinical case report that included longer term follow-up<sup>24</sup>. Two of the clinical case  
177 reports reported the use of medication throughout the study period; one introduced  
178 medication (olanzapine and chlorpromazine) at the beginning of the treatment period<sup>21</sup>, and  
179 the other reported that the client had been prescribed medication 10 weeks prior to the  
180 commencement of the CBT intervention, with a stable dose maintained throughout the  
181 intervention programme<sup>23</sup>. Neither study considered the potential impact of the medication  
182 when reporting treatment outcomes.

## 183 **Experimental and quasi-experimental designs**

### 184 **Multiple-baseline design**

185 One study employed an experimental multiple baseline across behaviours design with a 10  
186 year old male with borderline intellectual disability (WISC-R IQ = 79)<sup>25</sup>. The intervention  
187 took place on an inpatient unit, using behavioural treatment to target behaviours deemed to be  
188 reflective of depression in the participant. This included “inappropriate body position”, lack  
189 of eye contact, poor speech quality, and bland affect. Behavioural intervention involved  
190 specific skill training incorporating instruction, modelling, role-playing, and feedback of a  
191 more appropriate response in place of the inappropriate behaviour, over 20 minute sessions  
192 each day. Baseline was established over eight days for all behaviours, followed by  
193 introduction of the behavioural treatment for the first two behaviours simultaneously (six  
194 sessions), the third behaviour (five sessions), and the final behaviour (nine sessions).  
195 Frequency of target behaviours was recorded during each session, with reductions in each  
196 target behaviour observed following the introduction of the intervention, and maintenance  
197 improvements at a 12 week follow-up. While the study involved administration of a number  
198 of depression screening tools during their initial diagnostic process, these were not used to  
199 assess post-treatment outcomes.

## 200 **Uncontrolled trials**

201 Two studies were uncontrolled trials. One study was a case series with a pre-post design,  
202 reporting on existing patients seen in an inpatient setting<sup>26</sup>. This study identified patients (N =  
203 31) with an intellectual disability aged three to 16 years, diagnosed with depression according  
204 to DSM-III<sup>35</sup>. Gender was not reported. Treatment was described as the standard treatment  
205 used in the clinical setting. Individual psychotherapy was the primary treatment utilised,  
206 although frequency and duration of therapy were not specified. An unspecified number of  
207 participants were prescribed medication when it was clear the psychotherapy alone was not  
208 effective. The timing of the introduction of medication was not reported, and the impact was  
209 not considered in the reporting of outcomes. Outcomes were reported after approximately six

210 months of treatment before discharge from the facility. Eighty-seven percent of patients  
211 (n=27) were considered to have shown a clear clinical improvement by the time of discharge.  
212 However, a definition of clinical improvement was not reported, nor was the effect of  
213 medication.

214 The second pre-post design was an uncontrolled trial involving participants with autism and  
215 no co-occurring intellectual disability (n = 39, 82% male, mean age 10 years) to receive a  
216 structured intervention<sup>27</sup>. Participants in this study undertook a 12-week group CBT  
217 programme targeting social competence skills. Depressive symptoms were measured at the  
218 beginning and at the end of the treatment programme using the depression subscale score of  
219 the Behavior Assessment System for Children (BASC-II)<sup>36</sup>, a parent-report measure. No  
220 change was seen in depressive symptoms from the beginning to end of treatment, although  
221 improvements were seen in aggression, emotion control, and autism symptoms.

## 222 **Controlled trials**

223 Three studies were controlled trials. One trial evaluated the impact of a lifestyle intervention,  
224 a physical exercise programme, specifically Assisted Cycling Therapy (ACT), in a group of  
225 young people with Down Syndrome (n = 49, 59% male, mean age = 18.3 years (SD = 4.1  
226 years))<sup>29</sup>. ACT involved the use of a mechanical motor attached to a stationary exercise  
227 bicycle to increase the individual's cycling rate above their preferred voluntary cycling rate.  
228 Participants were counterbalanced to one of two active treatment groups ACT or Voluntary  
229 Cycling (VC)), although how the counterbalancing was achieved was not described, nor was  
230 it clear whether participants were randomised to each group. A No Cycling (NC) control  
231 group was recruited through convenience sampling, recruited through advertising in local  
232 communities. There were no group differences at baseline in terms of gender, chronological  
233 age, receptive language ability, hours of sport per week, or BMI. However, the ACT group

234 scored significantly higher on a measure of cognitive planning compared to both the VC and  
235 NC groups. Depression symptomatology was measured both pre- and post-treatment using  
236 the Children's Depression Inventory (CDI)<sup>14</sup>, with greater improvements on CDI scores seen  
237 in the ACT group when compared to both the VC and the NC control group at the end of the  
238 eight week therapy.

239 The second controlled trial reported on the impact of a group CBT programme for young  
240 people with Asperger Syndrome or autism without intellectual disability (n = 42, 72% male,  
241 mean age = 20.6 years (SD = 4.1))<sup>28</sup>. Participants were allocated to either treatment or  
242 waitlist control according to alternating order of study enrolment (i.e., pseudo-  
243 randomisations). The nine week CBT programme was developed with particular regard to the  
244 social difficulties often experienced by young people with autism. Depression was measured  
245 by the Depression subscale of the Depression, Anxiety and Stress Scales (DASS)<sup>37</sup> at pre-  
246 treatment, post-treatment, and again at three and nine month follow-ups. There was no  
247 significant difference between the groups post treatment. However, there was a significant  
248 decrease in DASS Depression scores for those participants with scores in the clinical range at  
249 pre-treatment. These improvements were maintained at both three and nine month follow-up.

250 The final controlled study also evaluated a group CBT programme for young people with  
251 autism with no intellectual disability (n = 23, 60% male, mean age = 15.75 years (SD =  
252 1.37))<sup>30</sup>. Participants were randomly allocated to either waitlist or control via a computer-  
253 generated random sequence programme. The ten week group CBT programme was designed  
254 specifically for young people with autism<sup>38</sup>. Depression was measured using both the DASS  
255 Depression subscale and the Beck Depression Inventory (BDI-II)<sup>15</sup> at pre-treatment, post-  
256 treatment, and at four and 12 week follow-ups. The authors reported no significant change in  
257 BDI-II scores from pre- to post- treatment, although a significant decrease was seen in DASS  
258 Depression scores for the treatment group.

259

260

261 **Research Questions 2 and 3: What are the experiences of young people and their**  
262 **families and treatments for depression? What are the experiences of professionals in**  
263 **delivering treatment for depression?**

264 No studies were identified that had a focus on evaluating the experiences of young people  
265 with intellectual disability and/or autism and their families in receiving psychological  
266 treatment for depression. Only two of the included studies reporting on treatments for  
267 depression also reported on participant experience<sup>22, 30</sup>. Santomauro *et al.*<sup>30</sup> gathered  
268 feedback from 15 young people with autism during their final group booster session, as a  
269 group discussion. Fourteen out of 15 young people reported enjoying the programme, with  
270 the fifteenth participant still recommending the programme for its usefulness. Participants  
271 considered the group setting the most beneficial aspect of the CBT programme. Greig and  
272 MacKay<sup>22</sup> briefly noted that the participant in their single case study felt that the intervention  
273 had worked for him in real life situations.

274 No studies evaluated the professional or clinician experience of delivering treatment for  
275 depression to children and young people with intellectual disability and/or autism.

#### 276 **Risk of bias**

277 Risk of bias was assessed for all studies. No studies were considered to have a low risk of  
278 bias. All of the clinical case reports (n = 4) were assessed as high risk of bias<sup>21-24</sup>. Clinical  
279 case reports are inherently biased; they have a high risk of publication bias, they are  
280 retrospective reports and subject to information bias in that they involve subjective  
281 interpretation by the author who is often the treating clinician, outcome assessment measures  
282 are often administered by the clinician, and causal relationships and generalisation are not

283 possible due to the nature of describing treatment outcome for one individual, often leading  
284 to overinterpretation of results and treatment effectiveness<sup>39</sup>. In addition to these overarching  
285 issues, the included clinical case reports had particular problems with outcome measures,  
286 including selecting inappropriate measures, not reporting how scores were calculated, and not  
287 reporting on all outcomes as stated.

288 Of the quasi-experimental and experimental studies, four studies were rated to have a  
289 moderate risk of bias, including the multiple baseline design<sup>25, 28-30</sup> and the remaining two  
290 rated as high risk of bias (both uncontrolled trials)<sup>26, 27</sup>. Reasons for ratings of moderate and  
291 high risk of bias included: no control group, no or poor randomisation when there was a  
292 control group, outcome measures administered by the clinician delivering treatment, use of  
293 outcome measures with unestablished psychometric properties in intellectual disability and/or  
294 autism, and not considering impact of confounding variables (e.g. medication).

295 [INSERT TABLES 2 AND 3 ABOUT HERE]

## 296 **Discussion**

297 This systematic search identified ten studies that evaluated psychological treatments for  
298 depression in children and young people with intellectual disability and/or autism. However,  
299 four of these were clinical case reports with a high risk of bias and thus are unable to directly  
300 inform a research evidence base to guide treatment<sup>21-24</sup>. The remaining six studies included  
301 four studies with either a single case experimental design<sup>25</sup>, an uncontrolled group design<sup>26, 27</sup>  
302 or a controlled group design<sup>28-30</sup>. The six experimental/quasi-experimental studies each  
303 focused on different treatments, different population groups, used different outcome measures  
304 for depression, and were all rated with a moderate or high risk of bias. Therefore, no  
305 conclusions can be drawn with any confidence about the suitability or effectiveness of any  
306 particular psychological or psychosocial intervention for treating depression in children and

307 young people with intellectual disability and/or autism. There was also essentially a complete  
308 lack of information about the experiences of young people or their families who received  
309 psychological intervention for depression, or the therapists who delivered the intervention.

### 310 **Study design**

311 High quality randomised controlled trials are essential to improve the evidence-base for  
312 effectiveness of these interventions. Only one of the three controlled trials employed  
313 adequate randomisation strategies<sup>30</sup>, with the others allocating participants based on order of  
314 enrolment<sup>28</sup>, or through counterbalancing, which was not thoroughly described<sup>29</sup>. Future  
315 studies should focus on developing well-designed randomised controlled trials to address this  
316 important gap in the literature.

317 In addition to the need for well-designed trials, future research should evaluate existing  
318 evidence-based psychological and psychosocial treatments for depression adapted  
319 specifically to meet the needs of children and young people with intellectual disability and/or  
320 autism. While a range of psychological and psychosocial interventions were identified in this  
321 review, only two of the experimental studies reported that the intervention used had been  
322 adapted for young people with autism<sup>28, 30</sup>. Importantly, none of the interventions described  
323 had been adapted for young people with intellectual disability. Development of new  
324 interventions tailored specifically for this population is also important. New interventions  
325 should be developed and evaluated through pilot studies, and further trialled in randomised  
326 controlled trials. The role of a parent / caregiver as support or facilitator within psychological  
327 interventions should also be considered. This approach has been successfully demonstrated in  
328 interventions with adults with intellectual disability (for example, Jahoda *et al.* <sup>40, 41</sup>).

329 Particularly important in any adaptation or development of interventions is collaboration with

330 the key stakeholders: young people with intellectual disability and/or autism, their parents  
331 and families, and the therapists delivering the interventions.

### 332 **Exclusion of intellectual disability**

333 Inclusion of children and young people with intellectual disability was extremely limited.  
334 Only four studies included participants with an intellectual disability<sup>21, 25, 26, 29</sup> and six studies  
335 included participants with a diagnosis of Asperger Syndrome or autism without co-occurring  
336 intellectual disability<sup>22-24, 27, 28, 30</sup>. No studies involved participants with both intellectual  
337 disability and autism, consistent with a recent meta-analysis demonstrating selection bias  
338 against participants with intellectual disability in autism research<sup>42</sup>. The exclusion of young  
339 people with intellectual disability was particularly evident in the controlled trials, with only  
340 the physical exercise intervention, involving no cognitive component, including participants  
341 with intellectual disability<sup>29</sup>. This is a significant gap in the literature in that we have limited  
342 evidence of effective interventions for depression in children with intellectual disability,  
343 despite knowledge that rates of mental health problems, in particular, depression, are  
344 prevalent in this population.

### 345 **Outcome measures**

346 Outcome measures of depression and depression symptomatology were inconsistent, and in  
347 some cases, not valid measures of depression. While a number of studies used validated  
348 measures and screening tools for depression, including the Revised Children's Anxiety and  
349 Depression Scale (RCADS) depression subscale<sup>23</sup>, the Hamilton Depression Rating Scale<sup>24</sup>,  
350 the DASS Depression scale<sup>28, 30</sup>, the CDI-II<sup>29</sup>, and the BDI-II<sup>30</sup>, others relied on subjective  
351 measurement such as clinical judgement, or changes in behaviour not necessarily indicative  
352 of depression. None of the depression measures used were developed or adapted for people  
353 with intellectual disability and/or autism. Further, selection of outcome measures was not

354 suitable in all studies. For example, the DASS is a tool designed for use with a typically  
355 developing adult population yet was used with children and young people as young as 13  
356 years in these studies. Use of suitable depression outcome measures is critical for future  
357 studies to ensure effectiveness in treating depression presenting in children and young people  
358 with intellectual disability and/or autism. Some caregiver-report measures of depressive  
359 symptoms in children and young people with intellectual disability already exist, such as the  
360 Developmental Behavior Checklist 2<sup>43</sup> and the Anxiety, Depression and Mood Scale<sup>44</sup>, and  
361 could be used to assess change in depressive symptoms. Some research has used adapted  
362 versions of the Children's Depression Inventory<sup>14</sup> for young people with intellectual  
363 disability<sup>45, 46</sup>. In addition, adapting existing self-report measures of depression validated for  
364 use with adults with intellectual disability, such as the Glasgow Depression Scale<sup>16</sup>, for use  
365 with children and young people, could be considered in future research.

### 366 **Strengths and limitations**

367 The current review was conducted with strong methodological rigour, in line with PRISMA  
368 guidelines and following a pre-registered protocol. Strengths of this review include the broad  
369 definition of psychological and psychosocial therapies used, ensuring all relevant treatments  
370 and interventions were identified, the inclusion of all publication types, including theses, and  
371 no restrictions on date of publication. Non-English publications were excluded, however two  
372 studies were identified from countries without English as a first language. A meta-analysis  
373 was not undertaken due to the small number of studies identified, their poor quality and  
374 moderate-high risk of bias.

### 375 **Summary and future directions**

376 This systematic review highlights a number of significant gaps in the literature for treatment  
377 of depression for children and young people with intellectual disability and/or autism, in

378 particular. The lack of well-designed randomised controlled trials was clear, as was the  
379 exclusion of young people with intellectual disability. The complete lack of research on  
380 psychological interventions for young people with intellectual disability was striking and  
381 concerning. Adaptation and development of specifically tailored psychological and  
382 psychosocial interventions for depression in children and young people with intellectual  
383 disability and/or autism, as well as measures of depression and depressive symptomatology,  
384 is an essential next step in the research. Future research should also ensure accurate records  
385 of medication are taken and considered when interpreting the effectiveness of a psychological  
386 intervention.

387 Further, evaluating experiences of both receiving treatment for depression (children and  
388 parents) and delivering treatment (therapists and professionals) is paramount in ensuring that  
389 interventions, both existing, adapted, and newly developed, meet the needs of the end user.  
390 Future research should ensure that families and professionals are consulted on the design of  
391 interventions and evaluations of their experiences are embedded within any study design.

392 It is important to note that these findings are not unique to the treatment of depression for  
393 children and young people with intellectual disability and/or autism. There is an absence of  
394 intervention research of any psychological treatments for any mental health disorder in this  
395 population<sup>7</sup>. Further, children and young people with severe intellectual disability are a  
396 particularly vulnerable group, and often neglected in research of mental health problems and  
397 intervention<sup>47</sup>. As highlighted in a recent systematic review, future research into  
398 psychological treatments for depression for children and young people with intellectual  
399 disability and/or autism should also be supported by the development of appropriate outcome  
400 measures of any mental health symptoms for this population<sup>48</sup>.

401 **Funding Statement.** This research received no specific grant from any funding agency,  
402 commercial, or not-for-profit sectors. L.A.C. is supported by an Australian Government  
403 Research Training Program (RTP) Scholarship. K.P. is the recipient of a University of New  
404 South Wales Australia Scientia PhD Scholarship.

405 **Declarations of Interest.** None

406 **Author Contribution.** K.M.G., K.P. and R.P.H. formulated the research questions, K.M.G.,  
407 K.P., R.P.H., and G.A.M. designed the study, K.P. and L.A.C. carried out the database  
408 search, K.P., L.A.C., K.M.G., G.A.M., and R.P.H. collected and analysed the data, L.A.C.,  
409 K.M.G., R.P.H., G.A.M., and K.P. wrote the manuscript or contributed to substantive reviews  
410 and revisions. All authors approved the final version of the manuscript and agree to be  
411 accountable for all aspects of the work.

## References

- 412  
413
- 414 1.Allerton LA, Welch V, Emerson E. Health inequalities experienced by children and young  
415 people with intellectual disabilities: a review of literature from the United Kingdom. *J*  
416 *Intellect Disabil.* 2011; **15**(4): 269-78.
- 417 2.Einfeld SL, Ellis LA, Emerson E. Comorbidity of intellectual disability and mental disorder  
418 in children and adolescents: A systematic review. *J Intellect Dev Disabil.* 2011; **36**(2): 137-  
419 43.
- 420 3.Maïano C, Coutu S, Tracey D, Bouchard S, Lepage G, Morin AJ, et al. Prevalence of  
421 anxiety and depressive disorders among youth with intellectual disabilities: A systematic  
422 review and meta-analysis. *J Affect Disord.* 2018; **236**: 230-42.
- 423 4.Douma JC, Dekker MC, Verhulst FC, Koot HM. Self-reports on mental health problems of  
424 youth with moderate to borderline intellectual disabilities. *J Am Acad Child Adolesc*  
425 *Psychiatry.* 2006; **45**(10): 1224-31.
- 426 5.Emerson E, Hatton C. Mental health of children and adolescents with intellectual  
427 disabilities in Britain. *Br J Psychiatry.* 2007; **191**(6): 493-9.
- 428 6.DeFilippis M. Depression in children and adolescents with Autism Spectrum Disorder.  
429 *Children.* 2018; **5**: 112.
- 430 7.Vereenoghe L, Langdon PE. Psychological therapies for people with intellectual  
431 disabilities: A systematic review and meta-analysis. *Res Dev Disabil.* 2013; **34**(11): 4085-  
432 102.
- 433 8.McCabe M, McGillivray J, Newton DC. Effectiveness of treatment programmes for  
434 depression among adults with mild/moderate intellectual disability. *J Intellect Disabil Res.*  
435 2006; **50**(4): 239-47.

- 436 9.National Institute for Health and Care Excellence (NICE). Mental health problems in  
437 people with learning disabilities: prevention, assessment and management [NG54]. [Online]  
438 2016. <https://www.nice.org.uk/guidance/ng54>.
- 439 10.National Institute for Health and Care Excellence (NICE). Depression in children and  
440 young people: identification and management [NG134]. [Online] 2019.  
441 <https://www.nice.org.uk/guidance/ng134>.
- 442 11.Daniel JT, Wood JJ. Cognitive behavioral therapy for children with autism: review and  
443 considerations for future research. *J Dev Behav Pediatr*. 2013; **34**(9): 702-15.
- 444 12.Lang R, Regester A, Lauderdale S, Ashbaugh K, Haring A. Treatment of anxiety in autism  
445 spectrum disorders using cognitive behaviour therapy: A systematic review. *Dev*  
446 *Neurorehabil*. 2010; **13**(1): 53-63.
- 447 13.Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting  
448 Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*.  
449 2009; **6**(7): e1000097.
- 450 14.Kovacs M. *Children's Depression Inventory: Manual*. Multi-Health Systems, 1992.
- 451 15.Beck AT, Steer RA, Brown GK. *Beck Depression Inventory Manual*. Psychological  
452 Corporation, 1996.
- 453 16.Cuthill FM, Espie CA, Cooper S. Development and psychometric properties of the  
454 Glasgow Depression Scale for people with a Learning Disability. *Br J Psychiatry*. 2003; **182**:  
455 347-53.
- 456 17.Monash Centre for Health Research and Implementation. *Evidence synthesis program*  
457 *template for critical appraisal of a randomised controlled trial*. Monash Centre for Health  
458 Research and Implementation, 2014.

459 18. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-  
460 Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.  
461 Ottawa Hospital Research Institute; 2019.

462 19. Blackmore R, Gray KM, Boyle JA, Fazel M, Ranasinha S, Fitzgerald G, et al. Systematic  
463 review and meta-analysis: The prevalence of mental illness in child and adolescent refugees  
464 and asylum seekers. *J Am Acad Child Adolesc Psychiatry*. 2020; **59**(6): 705-14.

465 20. Horner RH, Carr EG, Halle J, McGee G, Odom S, Wolery M. The use of single-subject  
466 research to identify evidence-based practice in special education. *Exceptional Children*. 2005;  
467 **71**(2): 165-79.

468 21. Fernandez A, Tom S, Stadler M, Cain H, Knudsen S. A multidisciplinary approach in  
469 treatment of major depressive disorder with psychotic features and mild intellectual  
470 disability. *Mental Health Aspects of Developmental Disabilities*. 2005; **8**(2): 45-51.

471 22. Greig A, MacKay T. Asperger's Syndrome and cognitive behaviour therapy: New  
472 applications for educational psychologists. *Educational & Child Psychology*. 2005; **22**(4): 4-  
473 15.

474 23. Loades ME. Evidence-based practice in the face of complexity and comorbidity: A case  
475 study of an adolescent with Asperger's Syndrome, anxiety, depression, and chronic pain. *J*  
476 *Child Adolesc Psychiatr Nurs*. 2015; **28**: 73-83.

477 24. Selvapandiyan J. Improvising pragmatic cognitive-behavioral therapy for depressed  
478 adolescents with Asperger Syndrome. *Prim Care Companion CNS Disord*. 2019; **21**(3):  
479 18102381.

480 25. Frame C, Matson JL, Sonis WA, Fialkov MJ, Kazdin AE. Behavioral treatment of  
481 depression in a prepuertal child. *J Behav Ther Exp Psychiatry*. 1982; **13**(3): 239-43.

482 26. Dosen A. Depressive conditions in mentally handicapped children. *Acta*  
483 *Paedopsychiatrica*. 1984; **50**: 29-40.

- 484 27.Habayeb S, Rich B, Alvord MK. Targeting heterogeneity and comoridity in children with  
485 Autism Spectrum Disorder through the Resilience Builder Group therapy program. *Child*  
486 *Youth Care Forum*. 2017; **46**: 539-57.
- 487 28.McGillivray JA, Evert HT. Group cognitive behavioural therapy program shows potential  
488 in reducing symptoms of depression and stress among young people with ASD. *J Autism Dev*  
489 *Disord*. 2014; **44**: 2041-51.
- 490 29.Ringenbach SDR, Holzapfel SD, Arnold NE, Nam K, Lopez C, Chen C-C, et al. Assisted  
491 Cycling Therapy (ACT) improves adaptive behaviors in adolescents with Down Syndrome.  
492 *Journal of Developmental and Physical Disabilities*. 2020; **35**: 535-52.
- 493 30.Santomauro D, Sheffield J, Sofronoff K. Depression in adolescents with ASD: A pilot  
494 RCT of a group intervention. *J Autism Dev Disord*. 2016; **46**: 572-88.
- 495 31.Gaus VL. *Cognitive-Behavioral Therapy for Adult Asperger Syndrome*. The Guilford  
496 Press, 2007.
- 497 32.Briere J. *Trauma scales for children and adolescents (TSCC)*. Psychological Assessment  
498 Resources (PAR), 1996.
- 499 33.Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety  
500 and Depression Scale in a clinical sample. *Behav Res Ther*. 2005; **43**(3): 309-22.
- 501 34.Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin*  
502 *Psychol*. 1967; **6**(4): 278-96.
- 503 35.American Psychiatric Association. *Diagnostic and Statistical Manual of Mental*  
504 *Disorders*. American Psychiatric Association, 1980.
- 505 36.Reynolds CR, Kamphaus RW. *BASC-2: Behavior assessment system for children* Pearson  
506 Education Inc., 2006.
- 507 37.Lovibond SH, Lovibond PF. *Manual for the Depression Anxiety Stress Scales*. Psychology  
508 Foundation, 1995.

509 38. Attwood T, Garnett M. *Exploring depression: Cognitive behaviour therapy to understand*  
510 *and cope with depression*. Jessica Kingsley Publishers, 2013.

511 39. Nissen T, Wynn R. The clinical case report: A review of its merits and limitations. *BMC*  
512 *Res Notes*. 2014; **7**: 264.

513 40. Jahoda A, Hastings R, Hatton C, Cooper S, Dagnan D, Zhang R, et al. Comparison of  
514 behavioural activation with guided self-help for treatment of depression in adults with  
515 intellectual disabilities: A randomised controlled trial. *Lancet Psychiatry*. 2017; **4**: 909-19.

516 41. Jahoda A, Melville C, Cooper S, Hastings R, Briggs A, Dagnan D, et al. BEAT-IT:  
517 Comparing a behavioural activation treatment for depression in adults with intellectual  
518 disabilities with an attention control: Study protocol for a randomised controlled trial. *Trials*.  
519 2015; **16**(595).

520 42. Russell G, Mandy W, Elliott D, White R, Pittwood T, Ford T. Selection bias on  
521 intellectual ability in autism research: A cross-sectional review and meta-analysis. *Mol*  
522 *Autism*. 2019; **10**(9).

523 43. Gray K, Tonge BJ, Einfeld S, Gruber C, Klein A. *Developmental Behavior Checklist 2*  
524 *(DBC2) (Manual)*. Western Psychological Services, 2018.

525 44. Esbensen AJ, Rojahn J, Aman MG, Ruedrich S. Reliability and validity of an assessment  
526 instrument for anxiety, depression, and mood among individuals with mental retardation. *J*  
527 *Autism Dev Disord*. 2003; **33**(6): 617-29.

528 45. Klein AM, Houtkamp EO, Salemink E, Baartmans JMD, Rinck M, van der Molen ML.  
529 Differences between self- and peer-rated likability in relation to social anxiety and depression  
530 in adolescents with mild intellectual disabilities. *Res Dev Disabil*. 2018; **80**: 44 - 51.

531 46. Weeland MM, Nijhof KS, Otten R, Vermaes IPR, Buitelaar JK. Beck's cognitive theory  
532 and the response style theory of depression in adolescents with and without mild to borderline  
533 intellectual disability. *Res Dev Disabil*. 2017; **69**: 39 - 48.

534 47.Vereenoghe L, Flynn S, Hastings RP, Adams D, Chauhan U, Cooper S, et al.  
535 Interventions for mental health problems in children and adults with severe intellectual  
536 disabilities: A systematic review. *BMJ Open*. 2018; **8**: e021911.

537 48.Flynn S, Vereenoghe L, Hastings RP, Adams D, Cooper S, Gore N, et al. Measurement  
538 tools for mental health problems and mental well-being in people with severe or profound  
539 intellectual disabilities: A systematic review. *Clin Psychol Rev*. 2017; **57**: 32-44.

540 49.American Psychiatric Association. *Diagnostic and Statistical Manual of Mental*  
541 *Disorders*. American Psychiatric Association, 2000.

542 50.Wechsler D. *Wechsler Intelligence Scales for Children, Third Edition*. Psychological  
543 Corporation, 1992.

544 51.World Health Organisation. *The ICD-10 Classification of Mental and Behavioural*  
545 *Disorders: Diagnostic Criteria for Research*. World Health Organisation, 1993.

546 52.Tyrer P, Nur U, Crawford M, Karlsen S, MacLean C, Rao B, et al. The Social Functioning  
547 Questionnaire: A Rapid and Robust Measure of Perceived Functioning. *Int J Soc Psychiatry*.  
548 2005; **51**(3): 265-75.

549 53.Wechsler D. *Manual for the Wechsler Intelligence Scale for Children-Revised*. The  
550 Psychological Corporation, 1974.

551 54.Achenbach T. The Child Behavior Profile: 1. Boys aged 6-11. *J Consult Clin Psychol*.  
552 1978; **46**: 478-88.

553 55.Petti T. Depression in hospitalized child psychiatric patients: Approaches to measuring  
554 depression. *J Am Acad Child Psychiatry*. 1978; **17**: 49 - 59.

555 56.Constantino J. *Social Responsiveness Scale*. Western Psychological Services, 2012.

556 57.Rutter M, Bailey A, Lord C. *Social Communication Questionnaire*. Western  
557 Psychological Service, 2003.

558 58.Walden TA, Harris VS, Catron TF. How I Feel: A self-report measure of emotional  
559 arousal and regulation for children. *Psychol Assess.* 2003; **15**(3): 399 - 412.

560 59.Hollon S, Kendall P. Cognitive self-statements in depression: Development of an  
561 automatic thoughts questionnaire. *Cognitive Therapy and Research.* 1980; **4**(4): 383 - 95.

562 60.Kendall P, Hollon S. Anxious self-talk: Development of the anxious self-statements  
563 questionnaire (ASSQ). *Cognitive Therapy and Research.* 1989; **13**(1): 81 - 93.

564 61.Sparrow SS, Cicchetti DV, Balla DA. *Vineland-II: Vineland adaptive behior scales.*  
565 Pearson, 2005.

566 62.Heller T. Self-efficacy scale. In: Exercise and Nutrition Education Curriculum for Adults  
567 with Developmental Disabilities (eds T Heller, BA Marks, SH Ailey). University of Illinois at  
568 Chicago, Rehabilitation Research and Training Center on Aging and Developmental  
569 Disabilities, Department of Disability and Human Development, 2001.

570 63.Gross JJ, John OP. Individual differences in two emotion regulation processes:  
571 Implications for affect, relationships, and well-being. *J Pers Soc Psychol.* 2003; **85**(2): 348 -  
572 62.

573

<b>Domain</b>	<b>Search terms</b>
Age group	adolescen* OR teen* OR youth OR child* OR “young person” OR juvenile OR paediatric OR pediatric
Intellectual disability and/or autism spectrum disorder	(mental* AND (handicap* OR retard* OR disab* OR impair* OR defici*)) OR ((learning OR intellect* OR development*) AND (difficult* OR disab* OR impair* OR disorder* OR handicap*)) OR ((Down* OR “Smith-Magenis” OR Rett* OR “Lesch-Nyhan” OR “Prader Willi” OR Angelman OR “Fragile X” OR “Cri-du-chat” OR “Cornelia de Lange” OR “de Lange” OR “Rubenstein-Taybi” OR velocardiofacial) AND syndrome*) OR (moron OR imbecile OR feeble-minded) OR (autis* OR ASD OR Asperger*)
Depression	(depress* AND (symptom* OR disorder OR thought* OR behavi*)) OR ((affective OR mood* OR emotion*) AND (disorder OR symptom* OR disturb*)) OR (depression OR dysthymi* OR melancholy*)
Treatment or intervention	therap* OR treat* OR intervention OR management OR counsel* OR training OR case OR psychotherap*

**Table 2** Clinical Case Reports

<b>Author, Year Country</b>	<b>Sample Size &amp; Description</b>	<b>Assessment of Depression</b>	<b>Treatment</b>	<b>Duration of Treatment</b>	<b>Outcome Measures</b>	<b>Results</b>	<b>Risk of Bias</b>
Fernandez <i>et al.</i> , 2005 <sup>21</sup>  USA	N = 1 Female 17 years old  Mild intellectual disability	Clinical intake interview: Major Depression (DSM-IV <sup>49</sup> )	Psychotherapy (weekly) - relaxation exercises, responding empathetically, and assistance with reframing  Therapeutic behavioural treatment (25-35 hours per week) - occurred both at school and group home  Medication – olanzapine and chlorpromazine introduced at the beginning of treatment. Olanzapine continued throughout treatment, fluoxetine replaced chlorpromazine at 7 months	8 months	Observation of target behaviours: compliance, lack of interest, oppositional behaviours and self-harm.  Number of times each behaviour occurred within the observational period was recorded monthly	Psychotherapy - improved coping skills, improvement in ability to express feelings, and improve capacity for self- advocacy  Behavioural treatment - decrease in frequency of maladaptive (target) behaviours, recurrence of oppositional behaviours in last 2 months of treatment  Improvement in GAF (DSM-IV <sup>49</sup> ) score from 25 (beginning of treatment) to 40 (end of treatment)	High

Author, Year Country	Sample Size & Description	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
Greig & MacKay, 2005 <sup>22</sup>  USA	N = 1 Male 12 years old  Asperger Syndrome WISC-III <sup>50</sup> FSIQ = 118	Clinically significant scores on self- report measure: Briere Trauma Scales, depression scale	CBT (The Homunculi) – a meta-cognitive visual aid using development of characters to support the use of tools to improve targeted behaviours, specifically developed by authors for people with autism	15 sessions	Measured post- intervention.  Emotional state: anxiety, depression, anger and stress scales of the Briere Trauma Scales <sup>32</sup>  Social competence and social skills: assessment by parent and self- report  School adjustment: teacher feedback	Emotional state on all scales, including depression, reduced to lower than clinically significant levels and were at the mean for the participant’s age group.  Improvements in perceived social competence and social skills, although still at lower levels than same- aged peers.  Reduction in concerns expressed by teacher about school adaptation.	High
Loades, 2015 <sup>23</sup>  USA	N = 1 Female 17 years old  Asperger Syndrome	Clinically significant score on self-report measure: Revised Children’s Anxiety and	CBT for low self- esteem with adaptations made for autism, although what adaptations were made was not	20 sessions	Progress assessments at Session 6, Session 12 and Session 20.	Clinically significant reduction in anxiety and depression at the end of treatment. Depression subscale score just below clinical range at end of treatment.	High

Author, Year Country	Sample Size & Description	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
		Depression Scale (RCADS) <sup>33</sup> (T score 85)	reported (weekly sessions)  Medication – antidepressant medication prescribed 10 weeks prior to commencement of therapy and continued throughout		RCADS scores (T scores on depression, overall anxiety, and specific anxiety subscales)		
Selvapandiyan, 2019 <sup>24</sup>  India	N = 2 Male, 17 years old Male, 18 years old  Asperger Syndrome	Clinical interview: Depressive Disorder (ICD- 10-DCR <sup>51</sup> )	Pragmatic CBT (specifically adapted for Asperger Syndrome to focus on difficulties with social communication <sup>31</sup> ) with acceptance and mindfulness techniques (weekly, 60-minute sessions)  Medication – both participants had been treated with psychotropic medication for some months	20 weeks	Measured at the end of each session. Additional follow-up period for 2 months post- intervention.  Hamilton Depression Rating Scale <sup>34</sup>  Social Functioning Questionnaire <sup>52</sup>	Both participants saw a reduction in scores on the Hamilton Depression Rating Scale to below clinically significant levels. Participants remained free from depressive symptoms over the follow-up period.  Improvement in scores on Social Functioning Questionnaire at the end of treatment.	High

<b>Author, Year Country</b>	<b>Sample Size &amp; Description</b>	<b>Assessment of Depression</b>	<b>Treatment</b>	<b>Duration of Treatment</b>	<b>Outcome Measures</b>	<b>Results</b>	<b>Risk of Bias</b>
			before commencing CBT				

Note: DSM = Diagnostic and Statistical Manual of Mental Disorders; GAF = Global Assessment of Functioning; WISC = Wechsler Intelligence Scale for Children; FSIQ = Full Scale Intelligence Quotient; CBT = cognitive behavioural therapy; ICD-10-DCR = The International Classification of Diseases-10 Classification of Mental and Behavioural Disorders, Diagnostic Criteria for Research

**Table 3** Experimental and Quasi Experimental Designs

Author, Year Country	Sample Size & Description			Randomisation	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
	Total sample	Treatment group	Control group							
Frame <i>et al.</i> , 1982 <sup>25</sup>  USA	N = 1 Male 10 years old  Borderline intellectual disability WISC-R <sup>53</sup> FSIQ = 79	NA	NA	NA	Psychiatric interview: Major Depressive Episode (DSM-III <sup>35</sup> )  Clinical cut off met on parent-report measures: Children's Depression Inventory <sup>14</sup> , Child Behavior Problem Checklist <sup>54</sup> , and Bellevue Index of Depression <sup>55</sup>	Behavioural training (20-minute sessions each weekday) - instructions, modelling, role-play, and performance feedback  Multiple baseline across behaviours design - 8-day pre-treatment baseline for all behaviours, followed by implementation of behavioural training for each target behaviour (first two behaviours introduced simultaneously, followed by the third behaviour	28 sessions	12-week follow-up after completion of treatment  Target behaviours: inappropriate body position, lack of eye contact, poor speech quality, bland affect  Frequency of target behaviours recorded during each baseline and intervention session	Each behaviour improved (i.e. less frequent occurrence) from baseline to when the intervention was introduced. Improvements in behaviour continued to be evident at 12-week follow-up (i.e. frequency of behaviours were still below the baseline rate).	Moderate

Author, Year Country	Sample Size & Description			Randomisation	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
	Total sample	Treatment group	Control group							
Dosen, 1984 <sup>26</sup> The Netherlands	N = 31 Age 3 – 16 years Gender not reported  Intellectual disability 32% IQ 30-50 48% IQ 50-80 20% IQ 80-90	NA	NA	NA	Evaluation of symptoms: Depression (DSM-III <sup>35</sup> )	Individual psychotherapy based on relationship therapy (frequency not reported; not reported whether adapted for people with intellectual disability)  Medication – tricyclic antidepressants prescribed for children who had little to no success with psychotherapy	Approximately 6 months	Clinical judgement on change in symptoms	87% showed clear clinical improvement on depressive symptoms, impact of medication not reported	High
Habayeb <i>et al.</i> , 2017 <sup>27</sup> USA	N = 39 82.1% male	NA	NA	NA	Depression subscale score of BASC-2 <sup>36</sup> :	Resilience Builder Program. Manualised	12 weeks	Measured at the end of the treatment programme.	Significant improvement in self-reported	High


Author, Year Country	Sample Size & Description			Randomisation	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
	Total sample	Treatment group	Control group							
	M <sub>age</sub> = 10 years (SD = 1.6 years)				overall sample mean clinically significant T-score	group CBT targeting social competence skills through a broader resilience framework (not an autism specific intervention).  12x one-hour sessions weekly, with 4-6 children in each group.		Internalising and externalising symptoms BASC-2 <sup>36</sup> , parent-report  Autism related social and communication impairments (Social Responsiveness Scale <sup>56</sup> , parent- report; Social Communication Questionnaire <sup>57</sup> , parent-report)  Positive and negative emotions and emotion control (How I Feel Questionnaire <sup>58</sup> , self-report)	emotion control following treatment.  No changes in depressive symptoms (measured by the BASC-2 Depression subscale).	

Author, Year Country	Sample Size & Description			Randomisation	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
	Total sample	Treatment group	Control group							
McGillivray & Evert, 2014 <sup>28</sup> Australia	N = 42 72% male M <sub>age</sub> = 20.6 years (SD = 4.1 years), range 15-25 years Asperger Syndrome (72%) and High Functioning Autism (28%)	N = 26 73.1% male M <sub>age</sub> = 20.27 years (SD = 4.39 years)	Waitlist control: N = 16 81.3% male M <sub>age</sub> = 20.50 years (SD = 3.40 years)	Allocation to group according to alternating order of enrolment	Scores above normal range on any of the following: DASS <sup>37</sup> , ATQ <sup>59</sup> , ASSQ <sup>60</sup>	Group CBT: “Think well, feel well and be well”, developed to address the social difficulties experienced by young people with autism  Weekly, 2-hour sessions	9 weeks	Measured post treatment, and at 3- and 9-month follow-ups.  DASS <sup>37</sup> Total, Depression, Anxiety, and Stress subscales  ATQ <sup>59</sup>  ASSQ <sup>60</sup>	Significant decrease in DASS Total and Depression subscale scores from pre- to post-treatment, regardless of allocation to treatment or control group  For participants with DASS Depression scores above the normal range, a significant decrease on DASS Depression scores was found between pre- and post-treatment for	Moderate

Author, Year Country	Sample Size & Description			Randomisation	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
	Total sample	Treatment group	Control group							
									those in the treatment group	
									No differences in DASS Depression scores at 3 or 9 month follow-up	
									DASS Depression scores at 9 month follow- up were significantly lower than at pre-treatment	
Ringenbach <i>et al.</i> , 2019 <sup>29</sup>  USA	N = 49 59% male M <sub>age</sub> = 18.3 years (SD = 4.1 years)  Down Syndrome	Assisted Cycling Therapy (ACT) group: N = 10 70% male	No cycling (NC) control: N = 11 45% male	Counterbalanced to ACT or VC groups  NC group made of convenience sample	Depressive symptoms assessed by Children's Depression Inventory (CDI) <sup>14</sup>	Cycling intervention, 3 x 30-minute sessions per week	8 weeks	Measured pre- and post- treatment  VABS <sup>61</sup>  CDI <sup>14</sup>	Participants in the ACT group had greater improvements on CDI scores when compared to the VC and	Moderate

Author, Year Country	Sample Size & Description			Randomisation	Assessment of Depression	Treatment	Duration of Treatment	Outcome Measures	Results	Risk of Bias
	Total sample	Treatment group	Control group							
	Mean mental age (PPV) = 5.5 years	Voluntary Cycling (VC) group: N = 8 100% male						Physical Activity Self-Efficacy <sup>62</sup>	NC groups. The VC and NC groups did not differ.	
Santomauro <i>et al.</i> , 2016 <sup>30</sup> Australia	N = 23 60% male M <sub>age</sub> = 15.75 years (SD = 1.37 years), range 13 – 18 years  Autism Spectrum Disorder VIQ > 85	N = 11 M <sub>age</sub> = 16 years (SD = 1.33 years)	Waitlist control: N = 12 M <sub>age</sub> = 15.50 years (SD = 1.43 years)	Allocation via computer-generated random sequence program	Score 14 or higher on BDI-II <sup>15</sup>	Group CBT: “Exploring Depression: cognitive behavior therapy to understand and cope with depression” <sup>38</sup> , designed for individuals with Asperger Syndrome  11 x 1-hour sessions 3-4 participants per group	10 weeks	Measured pre- and post-treatment, and 4 and 12 weeks post treatment  BDI-II <sup>15</sup>  DASS <sup>37</sup>  Emotion Regulation Questionnaire <sup>63</sup>	No significant change in BDI score from pre- to post-intervention or across the treatment and control groups  Significant decrease in DASS Depression scores for the treatment group when analysed independently of the waitlist control	Moderate

Note: BASC-2 = Behaviour Assessment System for Children, 2<sup>nd</sup> edition; DASS = Depression, Anxiety and Stress Scales; ATQ = Automatic Thoughts Questionnaire; ASSQ = Anxious Self-Statements Questionnaire; VABS = Vineland Adaptive Behavior Scales; CDI = Children's Depression Inventory; BDI = Beck Depression Inventory; VIQ = verbal IQ; PPV = Peabody Picture Vocabulary; DSM = Diagnostic and Statistical Manual of Mental Disorders



**Fig. 1** Study flow diagram.